Last reviewed · How we verify
Dermacid Silver (Lactic acid)
Lactic acid works as a topical antimicrobial and keratolytic agent that reduces bacterial colonization and promotes skin healing through acidification and exfoliation.
Lactic acid works as a topical antimicrobial and keratolytic agent that reduces bacterial colonization and promotes skin healing through acidification and exfoliation. Used for Infected or colonized wounds, Diabetic foot ulcers, Chronic wounds with bacterial burden.
At a glance
| Generic name | Dermacid Silver (Lactic acid) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Topical antimicrobial/keratolytic agent |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Lactic acid lowers skin pH to create an inhospitable environment for pathogenic bacteria, particularly in wound care and infected skin conditions. It also acts as a gentle exfoliant, promoting removal of necrotic tissue and supporting the skin barrier. The silver component provides additional antimicrobial properties through oligodynamic effects.
Approved indications
- Infected or colonized wounds
- Diabetic foot ulcers
- Chronic wounds with bacterial burden
Common side effects
- Local irritation or burning sensation
- Erythema at application site
- Mild pain on application
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dermacid Silver (Lactic acid) CI brief — competitive landscape report
- Dermacid Silver (Lactic acid) updates RSS · CI watch RSS
- Sanofi portfolio CI